These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29973877)

  • 1. Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.
    Li X; Liu C; Zhu X; Wei H; Zhang H; Chen H; Chen G; Yang D; Sun H; Shen Z; Zhang Y; Li W; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhong D; Niu J; Liu B; Ding Y
    Front Pharmacol; 2018; 9():643. PubMed ID: 29973877
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y
    Liu C; Zhang Y; Chen W; Lu Y; Li W; Liu Y; Lai X; Gong Y; Liu X; Li Y; Chen X; Li X; Sun H; Yang J; Zhong D
    Eur J Pharm Sci; 2019 Jan; 127():151-160. PubMed ID: 30326264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
    Zhang Y; Zhu X; Zhan Y; Li X; Liu C; Zhu Y; Zhang H; Wei H; Xia Y; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li Y; Ding Y; Zhong D
    Br J Clin Pharmacol; 2020 Sep; 86(9):1860-1874. PubMed ID: 32267573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet inhibitory activity, tolerability, and safety of vicagrel, a novel thienopyridine P2Y12 inhibitor.
    Li H; Chen H; Chen W; Xu H; Yuan F; Yang M; Sun H; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Sheng L; Liu C; Li X
    Medicine (Baltimore); 2020 Jan; 99(4):e18683. PubMed ID: 31977858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma.
    Liu C; Lu Y; Sun H; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhang Y; Chen X; Zhong D
    J Pharm Biomed Anal; 2018 Feb; 149():394-402. PubMed ID: 29154109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention.
    Zhao X; Ma S; Kang Y; Tang C; Liu B; Jiang H; Zheng M; Tang Y; Sun H; Liu Y; Lai X; Gong Y; Li Y; Qi Z; Ren L; Li J; Li Y; Han Y
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):806-814. PubMed ID: 35438151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
    Liu S; Wang Z; Tian X; Cai W
    Front Pharmacol; 2020; 11():591854. PubMed ID: 33424602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2.
    Zhang L; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li YG; He Y; Zhang EY; Yan X
    Eur J Pharm Sci; 2022 Oct; 177():106264. PubMed ID: 35868434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs.
    Qiu Z; Li N; Wang X; Tian F; Liu Q; Song L; Fan Z; Lu Y; Chen X
    J Pharm Sci; 2013 Feb; 102(2):741-9. PubMed ID: 23192851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
    J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, mass balance, and metabolism of [
    Zheng YD; Zhang H; Zhan Y; Bian YC; Ma S; Gan HX; Lai XJ; Liu YQ; Gong YC; Liu XF; Sun HB; Li YG; Zhong DF; Miao LY; Diao XX
    Acta Pharmacol Sin; 2021 Sep; 42(9):1535-1546. PubMed ID: 33244163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: Pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats.
    Xiao M; Qian C; Luo X; Yang M; Zhang Y; Wu C; Mok C; Lee P; Zuo Z
    J Ethnopharmacol; 2019 May; 235():100-110. PubMed ID: 30710735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a UPLC-MS/MS method for simultaneous determination of vicagrel and its major metabolites in rat or human plasma: An optimized novel strategy for the stabilization of vicagrel.
    Tai T; Zhou H; Zhu T; Jia YM; Ji JZ; Li YF; Mi QY; Xie HG
    J Pharm Biomed Anal; 2020 Feb; 179():112955. PubMed ID: 31866139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice.
    Jia YM; Gu TT; Ji JZ; Tai T; Zhang MR; Huang BB; Zhou H; Mi QY; Xie HG
    J Cardiovasc Pharmacol; 2018 Nov; 72(5):252-258. PubMed ID: 30358688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
    Husted S; Emanuelsson H; Heptinstall S; Sandset PM; Wickens M; Peters G
    Eur Heart J; 2006 May; 27(9):1038-47. PubMed ID: 16476694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
    Zou C; Zuo X; Huang J; Hua Y; Yang S; Yang X; Guo C; Tan H; Chen J; Chu Z; Pei Q; Yang G
    Front Pharmacol; 2019; 10():1231. PubMed ID: 31708774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.